Clinical Trials · NCT06015893
Semaglutide Therapy for Alcohol Reduction (STAR)
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Enrollment
- 63
- Start date
- Oct 2023
- Locations
- 1 site, United States
- Primary endpoint
- Determine whether semaglutide, compared to placebo, reduces alcohol drinking.